Works by Schiestl, Martin

Results: 12

Similarity assessment of quality attributes of biological medicines: the calculation of operating characteristics to compare different statistical approaches.

Published in:

AAPS Open, 2019, v. 5, n. 1, p. N.PAG, doi. 10.1186/s41120-019-0033-9

By:

Stangler, Thomas;
Schiestl, Martin

Publication type:

Article

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.

Published in:

Drug Design, Development & Therapy, 2017, v. 11, p. 1509, doi. 10.2147/DDDT.S130318

By:

Schiestl, Martin;
Zabransky, Markus;
Sörgel, Fritz

Publication type:

Article

The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.

Published in:

AAPS Journal, 2019, v. 21, n. 1, p. 1, doi. 10.1208/s12248-018-0275-9

By:

Mielke, Johanna;
Innerbichler, Franz;
Schiestl, Martin;
Ballarini, Nicolas M.;
Jones, Byron

Publication type:

Article

Maintaining consistent quality and clinical performance of biopharmaceuticals.

Published in:

Expert Opinion on Biological Therapy, 2018, v. 18, n. 4, p. 369, doi. 10.1080/14712598.2018.1421169

By:

Lamanna, William C.;
Holzmann, Johann;
Cohen, Hillel P.;
Guo, Xinghua;
Schweigler, Monika;
Stangler, Thomas;
Seidl, Andreas;
Schiestl, Martin

Publication type:

Article

The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.

Published in:

Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 2, p. 269, doi. 10.1177/1078155217731506

By:

Lamanna, William C.;
Heller, Katharina;
Schneider, Daniel;
Guerrasio, Raffaele;
Hampl, Veronika;
Fritsch, Cornelius;
Schiestl, Martin

Publication type:

Article

The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.

Published in:

2017

By:

Strand, Vibeke;
Girolomoni, Giampiero;
Schiestl, Martin;
Ernst Mayer, Robert;
Friccius-Quecke, Hilke;
McCamish, Mark

Publication type:

journal article

The Path Towards a Tailored Clinical Biosimilar Development.

Published in:

BioDrugs, 2020, v. 34, n. 3, p. 297, doi. 10.1007/s40259-020-00422-1

By:

Schiestl, Martin;
Ranganna, Gopinath;
Watson, Keith;
Jung, Byoungin;
Roth, Karsten;
Capsius, Björn;
Trieb, Michael;
Bias, Peter;
Maréchal-Jamil, Julie

Publication type:

Article

Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained.

Published in:

2018

By:

Aapro, Matti;
Krendyukov, Andriy;
Schiestl, Martin;
Gascón, Pere

Publication type:

Correction Notice

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained.

Published in:

BioDrugs, 2018, v. 32, n. 2, p. 129, doi. 10.1007/s40259-018-0262-9

By:

Aapro, Matti;
Krendyukov, Andriy;
Schiestl, Martin;
Gascón, Pere

Publication type:

Article

Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab.

Published in:

BioDrugs, 2013, v. 27, n. 5, p. 495, doi. 10.1007/s40259-013-0036-3

By:

Visser, Jan;
Feuerstein, Isabel;
Stangler, Thomas;
Schmiederer, Timo;
Fritsch, Cornelius;
Schiestl, Martin

Publication type:

Article

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

Published in:

Clinical Drug Investigation, 2018, v. 38, n. 6, p. 481, doi. 10.1007/s40261-018-0637-1

By:

Goldsmith, David;
Dellanna, Frank;
Schiestl, Martin;
Krendyukov, Andriy;
Combe, Christian

Publication type:

Article

Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

Published in:

2011

By:

Schiestl, Martin;
Stangler, Thomas;
Torella, Claudia;
Čepeljnik, Tadej;
Toll, Hansjörg;
Grau, Roger

Publication type:

Letter